Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, Integra LifeSciences (IART) reported revenue of $418.76 million, up 0.8% over the same period last year. EPS came in at $0.56, compared to $0.45 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $419.6 million, representing a surprise of -0.2%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.48.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Organic Revenue Growth: 0.7% compared to the 0% average estimate based on two analysts.
• Revenue- Tissue Technologies- Wound Reconstruction and Care: $81.31 million versus the two-analyst average estimate of $85.7 million. The reported number represents a year-over-year change of -4.1%.
• Revenue- Tissue Technologies- Total: $109.49 million versus $113.2 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.9% change.
• Revenue- Codman Specialty Surgical- Total: $309.27 million versus $303.91 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +1.8% change.
• Revenue- Tissue Technologies- Private Label: $28.19 million compared to the $27.5 million average estimate based on two analysts. The reported number represents a change of +4.8% year over year.

View all Key Company Metrics for Integra here>>>

Shares of Integra have returned +10% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research